Cargando…

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2

Detalles Bibliográficos
Autores principales:	Arora, Prerna, Kempf, Amy, Nehlmeier, Inga, Graichen, Luise, Schulz, Sebastian, Cossmann, Anne, Dopfer-Jablonka, Alexandra, Winkler, Martin S., Jäck, Hans-Martin, Behrens, Georg M. N., Pöhlmann, Stefan, Hoffmann, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110932/ https://www.ncbi.nlm.nih.gov/pubmed/35581351 http://dx.doi.org/10.1038/s41423-022-00870-5

Ejemplares similares

No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
por: Hoffmann, Markus, et al.
Publicado: (2022)

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
por: Arora, Prerna, et al.
Publicado: (2021)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
por: Hoffmann, Markus, et al.
Publicado: (2022)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
por: Arora, Prerna, et al.
Publicado: (2021)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
por: Sidarovich, Anzhalika, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Understanding Omicron: Transmissibility, immune evasion and antiviral intervention
por: Hoffmann, Markus, et al.
Publicado: (2022)

SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
por: Hoffmann, Markus, et al.
Publicado: (2021)

Health workers’ perception vs medically approved COVID-19 infection risk: the risk communication gap: Ellen Kuhlmann
por: Kuhlmann, E, et al.
Publicado: (2022)

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
por: Jedicke, Nils, et al.
Publicado: (2021)

Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study
por: Kuhlmann, Ellen, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2021)

Omicron spike protein: a clue for viral entry and immune evasion
por: Behrens, G. M. N., et al.
Publicado: (2022)

Role of rhesus macaque IFITM3(2) in simian immunodeficiency virus infection of macaques
por: Winkler, Michael, et al.
Publicado: (2019)

Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2
por: Reinke, Lennart Michel, et al.
Publicado: (2017)

H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice
por: Lambertz, Ruth Lydia Olga, et al.
Publicado: (2020)

Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein
por: Budhadev, Darshita, et al.
Publicado: (2023)

Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins
por: Plegge, Teresa, et al.
Publicado: (2019)

Successions: (art. 457-640 CC)
por: Guinand, Jean, et al.
Publicado: (1992)

Successions: (art. 457-640 CC)
por: Guinand, Jean, et al.
Publicado: (1999)

Cisco CCNA/CCENT Exam 640-802, 640-822, 640-816 Preparation Kit: With Cisco Router Simulations
por: Liu, Dale
Publicado: (2009)

Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins
por: Wrensch, Florian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uh5mibabh1qlm2vg0u59vfbi3r